Investors NYSE AMERICAN: LCTX Data Provided by Refinitiv. Minimum 15 minutes delayed. VIEW STOCK QUOTE Press Releases May 12, 2022 Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update May 05, 2022 Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022 May 03, 2022 RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration VIEW PRESS RELEASES Events & Presentations First Quarter 2022 Financial Results Earnings Call May 12, 2022 at 4:30 PM EDT 2022 Association for Research in Vision and Ophthalmology Annual Meeting May 2, 2022 Lineage Cell Therapeutics at B. Riley Securities Neuro & Ophthalmology Investor Conference Apr 27, 2022 at 3:30 PM EDT VIEW EVENTS & PRESENTATIONS
May 12, 2022 Lineage Cell Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
May 05, 2022 Lineage Cell Therapeutics to Report First Quarter 2022 Financial Results and Provide Business Update on May 12, 2022
May 03, 2022 RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Lineage Cell Therapeutics at B. Riley Securities Neuro & Ophthalmology Investor Conference Apr 27, 2022 at 3:30 PM EDT
